A Phase 3 interventional study of bosentan in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.
Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one is the 4th largest by enrollment, is one of 3 that started in 2011, is one of 7 in phase 3, and was the 11th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →
Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 3 Months to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 8 · Phase 4 5
First in 2003; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 37 across the 18 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 9 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one is the 24th largest by enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2011, is one of 31 in phase 3, and was the 27th registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial hypertension (PAH) \<12 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PAH diagnosis confirmed with right heart catheterization (RHC):
Exclusion Criteria:
Treatment with forbidden medication within 2 weeks or at least 5 times the half-life prior to randomization, whichever is the longest:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks
Drug: bosentan
2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks
Drug: bosentan
32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
Also known as: Tracleer, ACT-050088
Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan
Daily exposure was measured by the area under the plasma concentration-time curve over a period of 24 hours \[AUC(0-24)\]. Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. AUC(0-24) was calculated as a multiple of AUCtau, which is the AUC over a dosing interval (AUCtau x 2 for the b.i.d. dosing regimen and AUCtau x 3 for the t.i.d. regimen). As the smallest dose unit was 8 mg (1/4 tablet), it was not possible to achieve the exact target dose of 2 mg/kg. Therefore, AUC(0-24) was corrected to 2 mg/kg (target dose) \[AUC(0-24c)\].
Time frame: 0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment
Dose-corrected Maximum Plasma Concentration [Cmaxc] of Bosentan
Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. The peak plasma concentration (Cmax) of bosentan was directly obtained from the measured plasma concentrations and was dose-corrected to the target dose of 2 mg/kg (Cmaxc).
Time frame: 0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment
Time to Reach Cmax [Tmax] of Bosentan
Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. tmax was obtained directly from the measured plasma concentrations.
Time frame: 0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment
Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan Metabolites (Ro 478634, Ro 485033, Ro 641056)
Concentrations of the metabolites were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. Daily exposure to the metabolites corresponds to the area under the concentration-time curve \[AUC(0-24)\] of the corresponding metabolite over a period of 24 hours, and was calculated in the same manner as the primary endpoint. AUC(0-24c) was corrected to 2 mg/kg (target dose) \[AUC(0-24c)\].
Time frame: 0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment
Change From Baseline in WHO Functional Class at End of Study
The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension (PH): Class I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class IIII (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms. Number of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.
Time frame: Baseline, up to Week 24 on average
Change From Baseline in Global Clincial Impression Scale (GCIS) at End of Study
The GCIS is an assessment tool providing a single global assessment of the patient's current overall clinical condition: Very Good, Good, Neither Good or Bad, Bad and Very Bad. The assessment was performed both by the physician and the parents / legal representatives independently. Global clinical impression (GCI) at end of study was compared to GCI at baseline and the number of patients with clinical condition considered as worsened, improved or unchanged are determined.
Time frame: Baseline, up to Week 24 on average
Number of Patients With Treatment-emergent Liver Function Abnormalities
Number of patients with increase in alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) above 3 times upper limit of normal (ULN). The worst post-baseline value was considered. The treatment-emergent period was defined as study treatment start date up to 7 calendar days after study treatment end date.
Time frame: Baseline, up to Week 24
Number of Patients With Treatment-emergent Hemoglobin Abnormalities
Number of patients with marked hemoglobin decreases (absolute values below 10 g/dL). The worst post-baseline value was considered. The treatment-emergent period was defined as study treatment start date up to 7 calendar days after study treatment end date.
Time frame: Baseline, up to Week 24
Forty-five expert pediatric centers were initiated but only thirty of them enrolled children with pulmonary arterial hypertension (PAH)
| Milestone | Bosentan 2 mg/kg t.i.d. | Bosentan 2 mg/kg b.i.d. |
|---|---|---|
| Started | 31 | 33 |
| Completed | 31 | 33 |
| Not completed | 0 | 0 |
Daily exposure was measured by the area under the plasma concentration-time curve over a period of 24 hours \[AUC(0-24)\]. Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. AUC(0-24) was calculated as a multiple of AUCtau, which is the AUC over a dosing interval (AUCtau x 2 for the b.i.d. dosing regimen and AUCtau x 3 for the t.i.d. regimen). As the smallest dose unit was 8 mg (1/4 tablet), it was not possible to achieve the exact target dose of 2 mg/kg. Therefore, AUC(0-24) was corrected to 2 mg/kg (target dose) \[AUC(0-24c)\].
| h*ng/mL | Bosentan 2 mg/kg t.i.d. (PK Set) | Bosentan 2 mg/kg b.i.d. (PK Set) |
|---|---|---|
| Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan | 7275.1 (5468.2 to 9679.0) | 8535.4 (6936.0 to 10503.7) |
Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. The peak plasma concentration (Cmax) of bosentan was directly obtained from the measured plasma concentrations and was dose-corrected to the target dose of 2 mg/kg (Cmaxc).
| ng/mL | Bosentan 2 mg/kg t.i.d. (PK Set) | Bosentan 2 mg/kg b.i.d. (PK Set) |
|---|---|---|
| Dose-corrected Maximum Plasma Concentration [Cmaxc] of Bosentan | 527.9 (386.0 to 721.9) | 742.8 (572.8 to 963.2) |
Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. tmax was obtained directly from the measured plasma concentrations.
| hours | Bosentan 2 mg/kg t.i.d. (PK Set) | Bosentan 2 mg/kg b.i.d. (PK Set) |
|---|---|---|
| Time to Reach Cmax [Tmax] of Bosentan | 3 (1 to 8) | 3 (0 to 7.5) |
Concentrations of the metabolites were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. Daily exposure to the metabolites corresponds to the area under the concentration-time curve \[AUC(0-24)\] of the corresponding metabolite over a period of 24 hours, and was calculated in the same manner as the primary endpoint. AUC(0-24c) was corrected to 2 mg/kg (target dose) \[AUC(0-24c)\].
| h*ng/mL | Bosentan 2 mg/kg t.i.d. (PK Set) | Bosentan 2 mg/kg b.i.d. (PK Set) |
|---|---|---|
| AUC(0-24C) for Ro 478634 | 173.2 (126.2 to 237.6) | 200.4 (152.2 to 263.9) |
| AUC(0-24C) for Ro 485033 | 968.8 (723.3 to 1297.7) | 1352.5 (1073.4 to 1704.0) |
| AUC(0-24C) for Ro 641056 | 716.2 (543.5 to 943.8) | 1014.1 (801.2 to 1283.6) |
The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension (PH): Class I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class IIII (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms. Number of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.
| Participants | Bosentan 2 mg/kg t.i.d. | Bosentan 2 mg/kg b.i.d |
|---|---|---|
| Worsened WHO FC | 1 | 1 |
| Unchanged WHO FC | 27 | 25 |
| Improved WHO FC | 3 | 7 |
The GCIS is an assessment tool providing a single global assessment of the patient's current overall clinical condition: Very Good, Good, Neither Good or Bad, Bad and Very Bad. The assessment was performed both by the physician and the parents / legal representatives independently. Global clinical impression (GCI) at end of study was compared to GCI at baseline and the number of patients with clinical condition considered as worsened, improved or unchanged are determined.
| Participants | Bosentan 2 mg/kg t.i.d. | Bosentan 2 mg/kg b.i.d. |
|---|---|---|
| Worsened as per physician evaluation | 2 | 2 |
| Worsened as per parents evaluation | 4 | 3 |
| Unchanged as per physician evaluation | 24 | 24 |
| Unchanged as per parents evaluation | 19 | 19 |
| Improved as per physician evaluation | 5 | 7 |
| Improved as per parents evaluation | 8 | 11 |
Number of patients with increase in alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) above 3 times upper limit of normal (ULN). The worst post-baseline value was considered. The treatment-emergent period was defined as study treatment start date up to 7 calendar days after study treatment end date.
| Participants | Bosentan 2 mg/kg t.i.d. (ITT Set) | Bosentan 2 mg/kg b.i.d. (ITT Set) |
|---|---|---|
| ALT > 3 x ULN | 1 | 0 |
| AST > 3 x ULN | 0 | 0 |
Number of patients with marked hemoglobin decreases (absolute values below 10 g/dL). The worst post-baseline value was considered. The treatment-emergent period was defined as study treatment start date up to 7 calendar days after study treatment end date.
| Participants | Bosentan 2 mg/kg t.i.d. (ITT Set) | Bosentan 2 mg/kg b.i.d. (ITT Set) |
|---|---|---|
| Hemoglobin decrease with values < 10 g/dL | 1 | 3 |
| Hemoglobin decrease with values < 8 g/dL | 0 | 0 |
Collected over From the first dose of study treatment on Day 1 up to 7 days after treatment discontinuation, i.e. up to Week 25 on average. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bosentan 2 mg/kg t.i.d | — | 6/31 (19.4%) | 18/31 (58.1%) |
| Bosentan 2 mg/kg b.i.d | — | 4/33 (12.1%) | 18/33 (54.5%) |
| Event | Bosentan 2 mg/kg t.i.d | Bosentan 2 mg/kg b.i.d |
|---|---|---|
| ATRIAL SEPTAL DEFECT REPAIRSurgical and medical procedures | 1/31 | 0/33 |
| BODY TEMPERATURE INCREASEDInvestigations | 1/31 | 0/33 |
| BRONCHOPNEUMONIAInfections and infestations | 1/31 | 0/33 |
| GASTROENTERITISInfections and infestations | 1/31 | 0/33 |
| OXYGEN SATURATION DECREASEDInvestigations | 1/31 | 0/33 |
| PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders | 1/31 | 1/33 |
| PYREXIAGeneral disorders | 1/31 | 0/33 |
| RESPIRATORY DISTRESSRespiratory, thoracic and mediastinal disorders | 1/31 | 0/33 |
| RESPIRATORY TRACT INFECTION VIRALInfections and infestations | 1/31 | 0/33 |
| VIRAL INFECTIONInfections and infestations | 1/31 | 0/33 |
| Event | Bosentan 2 mg/kg t.i.d | Bosentan 2 mg/kg b.i.d |
|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 11/31 | 6/33 |
| PYREXIAGeneral disorders | 6/31 | 4/33 |
| NASOPHARYNGITISInfections and infestations | 3/31 | 5/33 |
| DIARRHOEAGastrointestinal disorders | 4/31 | 2/33 |
| VOMITINGGastrointestinal disorders | 4/31 | 1/33 |
| COUGHRespiratory, thoracic and mediastinal disorders | 3/31 | 0/33 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 3/31 | 0/33 |
| CONSTIPATIONGastrointestinal disorders | 2/31 | 1/33 |
| FLUSHINGVascular disorders | 2/31 | 0/33 |
| RASHSkin and subcutaneous tissue disorders | 2/31 | 1/33 |
| Age, Continuous(Years) | Bosentan 2 mg/kg t.i.d. | Bosentan 2 mg/kg b.i.d. | Total |
|---|---|---|---|
| Mean | 5.2 ± 3.81 | 4.5 ± 3.35 | 4.8 ± 3.57 |
| Sex: Female, Male(Participants) | Bosentan 2 mg/kg t.i.d. | Bosentan 2 mg/kg b.i.d. | Total |
|---|---|---|---|
| Female | 10 | 18 | 28 |
| Male | 21 | 15 | 36 |
| Region of Enrollment(Participants) | Bosentan 2 mg/kg t.i.d. | Bosentan 2 mg/kg b.i.d. | Total |
|---|---|---|---|
| Australia | 2 | 0 | 2 |
| Belarus | 1 | 2 | 3 |
| China | 2 | 4 | 6 |
| Czech Republic | 1 | 1 | 2 |
| France | 1 | 4 | 5 |
| Germany | 3 | 1 | 4 |
| Hungary | 3 | 0 | 3 |
| India | 1 | 2 | 3 |
| Israel | 0 | 2 | 2 |
| Italy | 1 | 0 | 1 |
| Mexico | 1 | 0 | 1 |
| Poland | 2 | 3 | 5 |
| Russia | 4 | 6 | 10 |
| Serbia | 2 | 3 | 5 |
| South Africa | 4 | 2 | 6 |
| Spain | 1 | 2 | 3 |
| USA | 1 | 1 | 2 |
| Ukraine | 1 | 0 | 1 |
| Etiology of pulmonary arterial hypertension (PAH)(Participants) | Bosentan 2 mg/kg t.i.d. | Bosentan 2 mg/kg b.i.d. | Total |
|---|---|---|---|
| Idiopathic | 15 | 14 | 29 |
| Heritable | 0 | 2 | 2 |
| PAH-Congenital heart disease | 2 | 6 | 8 |
| Associated PAH | 13 | 11 | 24 |
| Missing data | 1 | 0 | 1 |
| World Health Organization functional class (WHO FC)(Participants) | Bosentan 2 mg/kg t.i.d. | Bosentan 2 mg/kg b.i.d. | Total |
|---|---|---|---|
| FC I | 10 | 9 | 19 |
| FC II | 15 | 12 | 27 |
| FC III | 6 | 12 | 18 |
| PAH-specific therapy at baseline(Participants) | Bosentan 2 mg/kg t.i.d. | Bosentan 2 mg/kg b.i.d. | Total |
|---|---|---|---|
| Bosentan (adult tablet formulation) | 4 | 3 | 7 |
| Prostanoid | 1 | 0 | 1 |
| Phosphodiesterase type-5 (PDE-5) inhibitor | 13 | 10 | 23 |
| Bosentan / PDE-5 inhibitor combination | 2 | 2 | 4 |
| Bosentan /PDE-5 inhibitor /Prostanoid combination | 2 | 5 | 7 |
| None | 9 | 13 | 22 |
No study locations are listed for this record.
Ran from Mar 2011 to primary completion in Apr 2013, 24 months.
Results were first posted in Jun 2017, 4 years 2 months after primary completion. A results delay was requested in Aug 2014.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 24 months is below that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan
Pulmonary Arterial Hypertension →